Attention, access is restricted

    I confirm that I am a medical and /or pharmaceutical professional

    Sona-pharm - international team of professionals in pharmaceutical industry


    Ovitrelle / Choriogonadotropin alpha in the pharmacies:

    Pharmacy Ltd. 7 Ya

    Address: 7 Ya: Kiev - street. Sofievska, 6
    Phone: +38 (067) 823-77-79; +38 (044) 227-66-08; +38 (050) 469-95-07
    Work time: Mon-Fri - 8.00 – 21.00 Sat-Sun - 9.00 – 21.00

    Read more

    Pharmacy 24

    Address: Dnipro - Blvd. of Glory, 40
    Phone: (056) 794-00-24
    Work time: Mon-Fri: 8.00 - 21.00; Sat-Sun: 8.00-20.00

    Read more

    Pharmacy 24

    Address: Zaporozhye - street of the European, 5-a
    Phone: (0612) 28-70-50
    Work time: Mon-Fri: 08:00-20:00

    Read more

    Pharmacy 24

    Address: Ivano-Frankivsk - street. Garkushi, 24
    Phone: 067-560-46-35
    Work time: Mon - Sat 9:00 - 19:00, Sun day off

    Read more

    Pharmacy 24

    Address: Kiev - street. Academician Efremov, 3
    Phone: (044) 585-34-08
    Work time: Mon-Sun: 08:00-20:00

    Read more

    Pharmacy 24

    Address: Lviv - st. Prince Mstislav the Udatnogo, 5
    Phone: (032) 229-58-68
    Work time: 8.00 - 20.00

    Read more

    Pharmacy 24

    Address: Odessa - st. Shipbuilding, 1
    Phone: (048) 796-53-94
    Work time: 7.00 - 20.00

    Read more

    Pharmacy 24

    Address: Kharkiv - st. Poltava Way, 53/55
    Phone: (057) 728-41-45
    Work time: Mon-Fri: 8.00 - 20.00; Sat-Sun: 8.00-18.00

    Read more

    Ovitrelle / Choriogonadotropin alpha

    Active ingredient: 1 pre-filled syringe (0.5 ml) contains choriogonadotropin alfa 250 μg (6500 IU);

    Dosage form: Injectable solution.

    Pharmacotherapeutic group. Gonadotropins and other stimulants of ovulation.

    ATS code G03G A08.

    Registration Certificate No. UA / 1175/02/01


    Initiation of final maturation of follicles and luteinisation after follicular growth stimulation in women during suprovulation prior to the use of auxiliary reproductive technologies such as IVF;
    initiation of ovulation and luteinisation in patients with anovulation or oligovulation after stimulation of follicular growth.


    Tumors of the hypothalamus or pituitary gland;
    Hypersensitivity to the active substance or to any of the components of the drug;
    an increase in the size of the ovaries or cysts, not caused by the syndrome of polycystic ovary;
    gynecological bleeding of unknown etiology;
    carcinoma of the ovary, uterus or mammary glands;
    ectopic pregnancy in the previous 3 months;
    active forms of thromboembolic disorders.

    Ovitrelle should not be used in cases where it is impossible to obtain an effective response to treatment, for example:
    with primary ovarian failure;
    with malformations of genital organs incompatible with pregnancy;
    with fibroid tumors of the uterus, incompatible with pregnancy;
    women after menopause.

    Method of administration and dose.

    The drug should be used under the supervision of a physician experienced in the treatment of infertility.

    The drug is for subcutaneous administration. You can only enter a transparent solution that does not contain foreign particles.

    Such treatment regimens should be used.

    Women in superovulation prior to the use of auxiliary reproductive technologies, such as fertilization іn vitro (IVF)

    The contents of one pre-filled syringe of Ovitrelle (250 mcg) are administered 24-48 hours after the last injection of the follicle stimulating hormone (FSH) or human menopausal gonadotrophin (HMG), that is, when optimal follicular growth stimulation is achieved.

    Women with anovulation or oligovulation

    The contents of one pre-filled syringe of Ovitrelle (250 mcg) are administered after 24-48 hours after achieving optimal follicular growth stimulation. The patient is encouraged to have a sexual intercourse on the day of the introduction of Ovitrelle and the next day.